Craig Lindsley

A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery at Vanderbilt University has entered phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing. Read More

Meet Hannah Schaeffer, administrative manager for the Warren Center for Neuroscience Drug Discovery. Read More

What makes these results exceptional isn’t just the compounds themselves, it’s what they represent: the value of translational research grounded in real-world therapeutic goals. The partners chose to release these best-in-class tool compounds to the scientific community to accelerate further discovery. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

What makes these results exceptional isn’t just the compounds themselves, it’s what they represent: the value of translational research grounded in real-world therapeutic goals. The partners chose to release these best-in-class tool compounds to the scientific community to accelerate further discovery. Read More

In this episode of Quantum Potential, Craig Lindsley, William K. Warren, Jr. Professor of Medicine, University Distinguished Professor of Biochemistry, Chemistry and Pharmacology and executive director of the Warren Center for Neuroscience Drug Discovery, joins Provost C. Cybele Raver to discuss transformative research exploring how subtle tweaks to brain chemistry could change the way we treat neurodegenerative diseases and chronic pain. Lindsley shares how academic-industry collaborations drive innovation in drug discovery and highlights how Vanderbilt’s scientific workflow is enabling the broader research community to build on its breakthroughs. Read More

Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming cutting-edge research into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More

Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming Vanderbilt researchers’ work into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read More